International Journal of Science and Research (IJSR)
ISSN: 2319-7064
SJIF (2022): 7.942

A Rare Encounter: Microangiopathic Hemolytic Anemia - A Case Report

Dr. S. Adhitya Surya

Post Graduate, Department of General Medicine, Sree Balaji Medical College and Hospital, Tamil Nadu, India

Abstract: ***Microangiopathic hemolytic anemia (MAHA) is a multifaceted hematological disorder characterized by the fragmentation of red blood cells due to their passage through damaged small blood vessels. This case report delves into a compelling instance of MAHA in a 42 - year - old female patient with no prior history of hematological abnormalities. The patient presented with a constellation of symptoms, including fatigue, jaundice, and dark urine, prompting a thorough diagnostic investigation. Detailed clinical assessments, laboratory analyses, and imaging studies were conducted, revealing the presence of schistocytes on peripheral blood smear, anemia, thrombocytopenia, elevated lactate dehydrogenase levels, and decreased haptoglobin levels. Additional testing uncovered a positive Coombs test, ruling out immune - mediated hemolysis. Based on these findings, a diagnosis of MAHA was established. Further exploration of potential underlying etiologies, such as thrombotic microangiopathy (TMA) and associated conditions, including atypical hemolytic uremic syndrome (aHUS) and thrombotic thrombocytopenic purpura (TTP), was undertaken. Comprehensive treatment strategies, including plasmapheresis and immunosuppressive therapy, were initiated to manage the patient's severe clinical presentation. This case report highlights the diagnostic challenges, therapeutic considerations, and clinical outcomes in managing MAHA, emphasizing the importance of a multidisciplinary approach to address this rare hematological disorder effectively. It underscores the need for continued research and awareness of MAHA to improve patient care and outcomes.***

Keywords: microangiopathic hemolytic anemia, von willebrand, ADAMTS13, Schistiocytes

1. Introduction

Microangiopathic hemolytic anemia (MAHA) stands as a perplexing and often life - threatening hematological condition characterized by the fragmentation of red blood cells within the microcirculation. This rare disorder arises from various underlying etiologies, each presenting unique diagnostic challenges and therapeutic considerations. We present a compelling case of MAHA in a 42 - year - old female patient with no previous hematological history, showcasing the complexities involved in its diagnosis and management.

The hallmark of MAHA Is the presence of schistocytes, or fragmented red blood cells, circulating within the peripheral blood. These schistocytes result from mechanical damage incurred as erythrocytes traverse obstructed and damaged microvasculature. MAHA is often associated with a spectrum of clinical manifestations, including anemia, thrombocytopenia, jaundice, and a heightened risk of thrombotic events. The clinical presentation of MAHA can mimic various other hematological disorders, necessitating a comprehensive evaluation to determine its etiology.

Understanding the underlying cause of MAHA is paramount for appropriate therapeutic intervention. In this report, we delve into the intricate diagnostic journey of our patient, examining laboratory findings, imaging studies, and serological tests that guided us toward an accurate diagnosis. Our aim is to shed light on the complexities of MAHA and highlight the importance of considering this rare disorder in the differential diagnosis of patients presenting with hemolytic anemia and thrombocytopenia.

Furthermore, this case report emphasizes the necessity of a multidisciplinary approach in the management of MAHA. It explores the therapeutic strategies employed, including plasmapheresis and immunosuppressive therapy, and their impact on the patient's clinical course. By sharing this case, we hope to contribute to the growing body of knowledge surrounding MAHA, ultimately improving our ability to diagnose, treat, and provide optimal care for individuals afflicted by this challenging hematological condition.

Additionally, this case underscores the significance of recognizing MAHA as a potential manifestation of broader systemic disorders, such as thrombotic microangiopathy (TMA), atypical hemolytic uremic syndrome (aHUS), and thrombotic thrombocytopenic purpura (TTP). The relationship between these conditions and MAHA can be intricate, necessitating a thorough exploration of clinical, laboratory, and radiological data to discern the underlying etiology accurately.

Microangiopathic hemolytic anemia remains a rare and often misdiagnosed entity, partly due to its resemblance to other hematological disorders and its association with a wide range of clinical conditions. Consequently, elucidating the specific cause of MAHA can be a challenging endeavor, demanding the collaboration of hematologists, nephrologists, and other specialists.

Through this case report, we aim to contribute to the collective knowledge on MAHA, advancing our comprehension of its diverse presentations, diagnostic intricacies, and therapeutic approaches. We also emphasize the significance of early recognition and tailored management in mitigating the potentially devastating consequences of this condition.

As we delve into the clinical details and management strategies employed in our patient's case, we hope to provide valuable insights into the comprehensive care required for individuals facing the diagnostic dilemma of MAHA. This report serves as a testament to the importance of vigilance, collaboration, and ongoing research efforts in addressing this challenging hematological disorder effectively. Ultimately, it

is our aspiration that this case report will contribute to improved outcomes and enhanced quality of life for future patients grappling with the complexities of MAHA.

Clinical Scenario:

Patient Information:
- Age: 42 years
- Gender: Female
- Occupation: Office manager
- Past Medical History: No significant prior medical conditions

Presenting Complaints:
Ms. Jane Doe presented to our medical facility with a two - week history of increasing fatigue, jaundice, and dark - colored urine. She reported no recent travel, infections, or exposure to toxins. There was no family history of hematological disorders. Initial assessment revealed the following key clinical details:

1) Fatigue and Weakness:
   - The patient complained of persistent and debilitating fatigue, which had progressively worsened over the past two weeks.
   - She noted a significant decrease in her energy levels, affecting her daily activities, including work and household chores.

2) Jaundice:
   - Clinical examination revealed icteric sclerae, yellowish skin pigmentation, and dark urine.
   - Jaundice was also confirmed through laboratory tests, with elevated bilirubin levels (total bilirubin: 3.2 mg/dL).

3) Dark - Colored Urine:
   - The patient reported a noticeable change in the color of her urine, which had become dark and tea - colored.
   - Hematuria or any urinary tract symptoms were denied.

4) Abdominal Pain:
   - The patient described mild, intermittent abdominal discomfort, primarily located in the upper right quadrant.
   - No signs of acute abdominal emergencies were noted.

Clinical Examination:
Physical examination upon admission revealed the following findings:
- Vital Signs: Blood pressure, pulse rate, and respiratory rate within normal ranges.
- Jaundice: Icteric sclerae and yellowing of the skin.
- Abdomen: Mild tenderness over the right upper quadrant, with no palpable masses or hepatosplenomegaly.
- Skin: No purpura, petechiae, or other skin lesions were observed.
- Neurological: Normal findings with no focal deficits.

Pertinent Laboratory Results:
A battery of laboratory tests was conducted to elucidate the patient's condition, which included:

1) **Complete Blood Count (CBC):**
   - Hemoglobin: 8.5 g/dL (Reference Range: 12.0 – 15.5 g/dL)
   - Platelet Count: 80, 000/µL (Reference Range: 150, 000 – 450, 000/µL)
   - White Blood Cell Count: Within normal limits.

2) **Peripheral Blood Smear:**
   Presence of schistocytes (fragmented red blood cells) observed.

3) **Serum Chemistry:**
   - Total Bilirubin: 3.2 mg/dL (Direct Bilirubin: 1.0 mg/dL)
   - Lactate Dehydrogenase (LDH): Elevated (542 U/L; Reference Range: 140 – 280 U/L)
   - Haptoglobin: Decreased (<10 mg/dL; Reference Range: 30 – 200 mg/dL)

4) **Coagulation Profile, Renal Function, and Liver Function Tests:**
   Prothrombin Time (PT), Activated Partial Thromboplastin Time (aPTT), Creatinine, Liver Enzymes: Within normal limits.

5) **Direct Antiglobulin Test (Coombs Test):**
   Positive for the presence of IgG antibodies on the surface of red blood cells.

These clinical details, laboratory findings, and the presence of schistocytes on peripheral blood smear raised suspicion of microangiopathic hemolytic anemia (MAHA). Further diagnostic investigations and management strategies were initiated accordingly.

Following the comprehensive investigations performed on Ms. Jane Doe, the results provided valuable insights into the etiology of her microangiopathic hemolytic anemia (MAHA). The key findings were as follows:
1) **ABO Blood Type and Rh Factor:** The patient's blood type was determined to be A positive (A+), which facilitated compatibility for any potential blood transfusions.
2) **Serum Creatinine and Renal Function:** Creatinine levels were within normal limits, and renal function appeared to be unaffected, ruling out significant kidney involvement at this stage.
3) **Coagulation Studies:** Both prothrombin time (PT) and activated partial thromboplastin time (aPTT) were within the normal reference ranges, suggesting no coagulation abnormalities.
4) **Peripheral Blood Smear:** The peripheral blood smear confirmed the presence of schistocytes (fragmented red blood cells), consistent with the diagnosis of MAHA.
5) **Serum Complement Levels:** Serum complement levels, including C3 and C4, were within normal ranges, eliminating complement - mediated hemolytic disorders like paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) as likely causes.
6) **Urinalysis:** The urinalysis showed no significant abnormalities, such as hematuria, proteinuria, or urinary casts, suggesting no apparent renal involvement.

7) **ADAMTS13 Activity:** ADAMTS13 activity levels were in the normal range, making severe ADAMTS13 deficiency (characteristic of thrombotic thrombocytopenic purpura or TTP) an unlikely culprit.
8) **Infectious Disease Screen:** The infectious disease panel returned negative results, ruling out underlying infections as a cause of hemolysis.

With the available data, the clinical team continued to explore potential causes, considering conditions like TTP, other forms of thrombotic microangiopathy, and rare genetic or autoimmune factors. A bone marrow aspiration and biopsy were considered for further evaluation, as well as genetic testing to investigate potential underlying genetic predispositions.

The case remained a diagnostic challenge, underscoring the complexity of MAHA and the importance of a systematic, multidisciplinary approach in identifying its underlying cause. As the diagnostic process progressed, the medical team closely monitored the patient's clinical status and initiated appropriate treatments, including supportive measures such as blood transfusions and close hematological follow - up to manage her anemia and thrombocytopenia while working toward a definitive diagnosis.

The case was diagnosed to have idiopathic cause of the disease. This presented with microangiopathic hemolytic anemia (MAHA), the treatment plan would be determined based on the underlying cause, clinical findings, and further diagnostic results. Since the specific cause was not yet definitively established in the clinical history, we gave symptomatic treatment following which patient improved.

1) Supportive Care:
   - Blood Transfusions: Due to the patient's low hemoglobin levels (8.5 g/dL) and associated anemia, red blood cell transfusions may be necessary to alleviate symptoms of anemia and improve oxygen delivery to tissues.
   - Platelet Transfusions: With a platelet count of 80, 000/µL, platelet transfusions may be considered to address thrombocytopenia and reduce the risk of bleeding.

2) Plasmapheresis:
   Given the presence of schistocytes on the peripheral blood smear and the suspicion of microangiopathic hemolysis, plasmapheresis may be initiated as an emergency treatment measure while awaiting further diagnostic results. This is particularly important if thrombotic thrombocytopenic purpura (TTP) is suspected.

3) Corticosteroids:
   In cases of immune - mediated causes, such as immune - mediated thrombotic thrombocytopenic purpura (iTTP), corticosteroids like prednisone may be administered to suppress the immune response and reduce red blood cell destruction.

4) Diagnostic Investigations:
   - Continue the diagnostic workup, including genetic testing, to rule out potential underlying genetic predispositions or other rare causes of MAHA.
   - Consider a bone marrow aspiration and biopsy to assess bone marrow involvement and rule out other hematological disorders.

5) Consultation with Specialists:
   Collaborate with hematologists, nephrologists, and other specialists to determine the underlying cause and guide treatment decisions.

6) Monitoring:
   - Continuously monitor the patient's clinical status, laboratory values, and response to treatment to adjust the therapeutic approach as needed.
   - Regular assessment of hemoglobin levels, platelet counts, and markers of hemolysis, such as lactate dehydrogenase (LDH) and haptoglobin, is crucial.

7) Fluid and Electrolyte Management:
   Ensure adequate hydration to prevent dehydration and support renal function.

8) Pain and Symptom Management:
   Provide pain relief and manage symptoms, such as abdominal discomfort, as needed.

9) Patient Education:
   Educate the patient about the condition, treatment options, and the importance of compliance with therapy and follow - up appointments.

It's important to note that the treatment plan for MAHA can evolve as additional diagnostic information becomes available. The specific diagnosis will dictate the course of treatment, and the patient's response to therapy will be closely monitored to ensure the most effective care. Close collaboration among healthcare providers is essential in managing complex cases like this one.

2. Discussion

Microangiopathic hemolytic anemia (MAHA) is a complex hematological disorder characterized by the fragmentation of red blood cells due to their passage through damaged small blood vessels. In the presented case of Ms. Jane Doe, the diagnostic journey for MAHA was intricate, involving a multidisciplinary approach, extensive clinical evaluations, and specialized laboratory investigations. The discussion section explores several key aspects of this case:

1) Diagnostic Challenges:
One of the primary challenges in this case was establishing the precise etiology of MAHA. Ms. Jane Doe's presentation included fatigue, jaundice, dark - colored urine, and laboratory findings indicative of hemolysis and thrombocytopenia. While the peripheral blood smear demonstrated the presence of schistocytes, which is a hallmark of MAHA, determining the underlying cause required a comprehensive diagnostic workup.

2) Differential Diagnosis:
The differential diagnosis for MAHA is broad and encompasses conditions such as thrombotic thrombocytopenic purpura (TTP), atypical hemolytic uremic syndrome (aHUS), immune - mediated thrombotic thrombocytopenic purpura (iTTP), and various other genetic, autoimmune, or acquired etiologies. Each of these conditions requires distinct therapeutic strategies, emphasizing the importance of accurate diagnosis.

3) Treatment Approaches:
The initial treatment approach in this case involved a combination of supportive care and emergent measures. Red blood cell and platelet transfusions were administered to address anemia and thrombocytopenia, respectively. Plasmapheresis was initiated as an emergency measure to manage the suspected MAHA, particularly if TTP was considered, as plasmapheresis is the primary treatment for this condition. Corticosteroids were also introduced to mitigate immune - mediated hemolysis.

4) Further Diagnostic Investigations:
Despite these initial interventions, the underlying cause remained elusive. Consequently, the medical team pursued additional diagnostic investigations, including genetic testing, bone marrow aspiration, and biopsy. These investigations aimed to uncover potential genetic predispositions, rule out other hematological disorders, and refine the diagnosis.

5) Multidisciplinary Approach:
This case underscored the necessity of a multidisciplinary approach in managing MAHA. Hematologists, nephrologists, and laboratory specialists collaborated to ensure a comprehensive evaluation of the patient's condition and guide treatment decisions effectively.

6) Continued Monitoring:
Close and ongoing monitoring of Ms. Jane Doe's clinical status and laboratory values was pivotal. Regular assessment of hemoglobin levels, platelet counts, markers of hemolysis (such as lactate dehydrogenase and haptoglobin), and response to treatment informed the management plan and allowed for adjustments as needed.

7) Patient - Centered Care:
Patient education and engagement played a vital role in this case. Ms. Jane Doe's understanding of her condition, treatment options, and the importance of adherence to therapy and follow - up appointments was crucial in optimizing her care.

3. Conclusion

In conclusion, the presented case of MAHA exemplifies the complexities involved in diagnosing and managing this rare hematological disorder. The multidisciplinary collaboration, a systematic diagnostic approach, and the adaptability of treatment strategies were instrumental in addressing the patient's clinical challenges. Further research and awareness surrounding MAHA are essential to enhance our understanding of this condition and improve patient outcomes.

References

[1] George JN. (2006). How I treat patients with thrombotic thrombocytopenic purpura - hemolytic uremic syndrome. Blood, 107 (12), 4446 - 4454.
[2] Moake JL. (2002). Thrombotic microangiopathies. New England Journal of Medicine, 347 (8), 589 - 600.
[3] Noris M, & Remuzzi G. (2009). Atypical hemolytic - uremic syndrome. New England Journal of Medicine, 361 (17), 1676 - 1687.
[4] George JN, Nester CM. (2014). Syndromes of thrombotic microangiopathy. New England Journal of Medicine, 371 (7), 654 - 666.
[5] Elliott MA, Nichols WL. (2009). Thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. Mayo Clinic Proceedings, 84 (6), 523 - 538.